Gliclazide Management on Sick Days
Gliclazide should be temporarily stopped (dose reduced or held) during sick days when a patient is acutely ill and unable to eat normally, with close glucose monitoring every 4-6 hours to prevent hypoglycemia. 1, 2, 3
Rationale for Stopping Gliclazide
Gliclazide is a sulfonylurea that stimulates insulin secretion regardless of food intake, creating significant hypoglycemia risk when oral intake is reduced during acute illness. The Endocrine Society guidelines explicitly recommend discontinuing oral hypoglycemic agents and transitioning to insulin therapy for the majority of hospitalized patients with type 2 diabetes during acute illness 1. This recommendation is based on the fact that contraindications to oral agents are frequently present during hospitalization, and these agents can cause dangerous delays in achieving glycemic targets while increasing hypoglycemia risk 1.
Specific Sick Day Management Protocol
When to Hold Gliclazide
Stop gliclazide when any of these triggers occur 3:
- Vomiting or diarrhea causing significant fluid losses
- Anorexia or nausea resulting in significantly decreased fluid intake
- New lightheadedness, dizziness, or fainting, particularly with position changes
- Decreased weight (≥3 kg in 2 days)
- Decreased urine output
Duration of Holding
- Hold for up to 72 hours or until symptoms resolve, whichever comes first 3
- If symptoms persist beyond 72 hours, contact healthcare provider immediately 2, 3
Glucose Monitoring During Sick Days
- Check blood glucose every 4-6 hours while awake 1, 4
- Reassess therapy when glucose falls below 100 mg/dL (5.6 mmol/L) 1
- Modify treatment when glucose drops below 70 mg/dL (3.9 mmol/L) 1
Critical Safety Considerations
If the patient has already taken their daily gliclazide dose before becoming ill, they must attempt to eat foods to prevent hypoglycemia until the medication effect wears off (approximately 12-24 hours) 3. This is a crucial pitfall—the sulfonylurea effect cannot be reversed once the dose is taken.
When to Seek Emergency Care
Contact healthcare provider immediately for 2, 3:
- Reduced consciousness or new confusion
- Vomiting >4 times in 12 hours or inability to keep fluids down
- Recurrent low blood glucose readings
- Systolic BP <80 mmHg or drop of 20 mmHg systolic/10 mmHg diastolic
Transition to Insulin if Needed
For patients requiring hospitalization or with prolonged illness, transition from gliclazide to scheduled subcutaneous insulin 1:
- Discontinue gliclazide completely upon hospital admission
- Calculate total daily insulin dose: 0.2-0.3 units/kg for elderly (≥70 years) or those with GFR <60 mL/min; 0.4 units/kg for glucose 140-200 mg/dL; 0.5 units/kg for glucose 201-400 mg/dL 1
- Distribute as 50% basal insulin (glargine/detemir once or twice daily) and 50% nutritional insulin (rapid-acting before meals) 1
- For patients NPO (nothing by mouth): give basal insulin alone with correction doses of rapid-acting insulin every 4-6 hours 1
Resuming Gliclazide
Resume gliclazide at usual doses 3:
- Within 24-48 hours of eating and drinking normally
- As soon as symptoms improve and normal eating resumes
- Only after confirming patient can maintain adequate oral intake
Important Caveats
The elderly, debilitated, malnourished, and those with renal or hepatic impairment are particularly susceptible to prolonged hypoglycemia from sulfonylureas 5. In these populations, consider not restarting gliclazide and instead transitioning to safer alternatives with lower hypoglycemia risk after the acute illness resolves.
Hypoglycemia from gliclazide may be prolonged and difficult to recognize in elderly patients or those on beta-blockers 5. The risk is highest when caloric intake is deficient, after prolonged exercise, with alcohol ingestion, or when multiple glucose-lowering drugs are used 5.